Computer-aided drug screening of anti-Neobenedenia melleni drugs based on annexin B1 in farmed pearl grouper (Epinephelus fuscoguttatus♀ × Epinephelus lanceolatus ♂)
In vivo validation of eleven compounds identified abamectin (Aba) as the most effective anti-Neobenedenia agent, achieving complete parasite elimination at 0.16 mg/L, corresponding to a therapeutic index of approximately 7.7.
Abstract
Monogenean capsalids of the genus Neobenedenia are widespread parasites of wild and farmed marine fish and represent a major threat to grouper mariculture in China, whose production reached approximately 294,000 tonnes in 2025. The development of effective drugs to control and prevent these infections is therefore urgently needed. Annexins, which have been identified in Neobenedenia and other parasites, differ markedly from their host counterparts, making them potentially attractive targets for antiparasitic therapeutics. Here, we performed a computer-aided drug discovery screen, employing Neobenedenia melleni annexin B1 as the molecular target against a library of 1,456,161 small molecules. The three-dimensional structure of annexin B1 was first predicted using AlphaFold 3, SWISS-MODEL, and I-TASSER, and the most accurate model (AlphaFold) was selected for structure-based virtual screening. In vivo validation of eleven compounds identified abamectin (Aba) as the most effective anti-Neobenedenia agent, achieving complete parasite elimination at 0.16 mg/L. Owing to its low toxicity to the host grouper (24-h LC50 = 0.254 mg/L), abamectin was selected for further investigation. Abamectin exhibited potent anthelmintic activity against N. melleni, with a 24-h bath exposure yielding an EC50 of 0.033 mg/L and complete parasite elimination at 0.16 mg/L, corresponding to a therapeutic index of approximately 7.7. To elucidate the antiparasitic mechanism, we performed long-timescale (1000 ns) molecular dynamics simulations of the annexin B1-abamectin complex, enabling atomic-level analysis of the essential protein motions involved in their interaction. The interaction profile between annexin B1 and abamectin was dominated by hydrophobic contacts and water bridges, involving residues TYR-210, GLU-214, GLU-244, and SER-247, which path a way for further drug optimization.
Findings highlight compound D as a promising lead candidate for short-bath therapy against N. melleni and suggest that cytoskeletal disruption through β-tubulin interaction represents a plausible mechanism of action.
A phenotypic screening approach was applied to identify compounds active against S. chrysophrii, and niclosamide, one of the most potent compounds identified, demonstrated a parasiticidal activity more than 11,000-times greater than praziquantel, a reference chemotherapeutic agent commonly used against fish polyopistho...
Ana León, Teresa Pirollo, Elnaz Aledavood et al.· Veterinary parasitology· 0 citations
Findings collectively underscored P. ostreatus as a potential natural antiparasitic agent, indicating that its sterol-rich extract may demonstrate oocysticidal activity via multi-target molecular interactions and direct impacts on oocyst integrity.
Amal M. Marey, M. Dkhil, S. Kasem et al.· Cell Biochemistry and Biophy...· 0 citations
Amentoflavone and myo-inositol possess strong gene-modulatory and antiviral activities, and amentoflavone can be considered a lead compound for the developing of antiviral therapeutic agents, with a specific focus on HIV-2 integrase.
Zvikomborero Zinhumwe, Praveen Mallari, Shruti Mehta et al.· Journal of the Brazilian Che...· 0 citations
Findings indicate that the tested compounds possess potential as antibacterial and quorum sensing inhibitory agents by targeting LuxR, however, further in vitro and in vivostudies are required to validate their biological activity and therapeutic potential.
Ziyan Iswahyudi, M. Fadjar, Y. Maimunah et al.· Journal of aquaculture and f...· 0 citations
Andrographolide represents a promising in vitro anthelmintic hit against A. cantonensis and warrants further preclinical investigation, supporting a preliminary selectivity profile.
Fabiana R. S. Tominaga, Davi Luna-Tavares, Lucas Fukui-Silva et al.· Pharmaceuticals· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.